key: cord-0744479-dzdgufgo
authors: AlBahrani, Salma; AlBarraK, Ali; Alghamdi, Othman Ali; Abdullah alghamdi, Mesfer; Hakami, Fatimah H.; Abaadi, Asmaa K. Al; Alkhrashi, Sausan A.; Alghamdi, Mansour Y.; Almershad, Meshael M.; Alenazi, Mansour Moklif; ElGezery, Mohamed Hany; Jebakumar, Arulanantham Zechariah; Al-Tawfiq, Jaffar A.
title: Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Vaccinee in Saudi Arabia
date: 2021-07-25
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.052
sha: e82b42bd2c68d211f098baa758d28de9cbaafd7d
doc_id: 744479
cord_uid: dzdgufgo

INTRODUCTION: : The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. Here, we estimated the safety and reactogenicity of the ChAdOx1-S vaccine as administered to adults after the first dose. METHODS: : This is a cross-sectional study and included 1592 randomly selected vaccinees from April to May, 2021. Questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. RESULTS: : Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438; 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and no hospitalization. CONCLUSION: : In this study, we observed no major side effects of the ChAdOx1-S and no reported breakthrough infection during the observation period.

Methods: This is a cross-sectional study and included 1592 randomly selected vaccinees from April to 36 May, 2021. Questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first 37 vaccine dose. 38

Results: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (+ 9.6) and 81% were 39 males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first call. The most 40 common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438; 41 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men 42 were more likely to report fever (76.9% vs. 23 

This study included 1592 vaccinees who received first dose of ChAdOx1-S vaccine and the mean age (+ 106 SD) was 37.4 (+ 9.6) (range 19-83) years (figure 1), and 81% were males. Of all the vaccinees, 553 107 (34.7%) reported a reaction on the first call and none reported any reaction on the second call (Table 1) . 108 (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). 110

Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) 111 and pain at the injection site (77.3% vs. 22.7%, P = 0.01). The rate of post-vaccine COVID-19 infection 112 was 0.5% and no hospitalization. Males had an overall more reactions than females (76.7% vs. 23.3%; P 113 = 0.001). In addition, there was a substantial difference in the rate of pain at the site of injection, skin 114 rash and fever between males and females ( Older individuals were more likely to report symptoms compared to the younger population (table 3) . showed 67% efficacy in preventing moderate to severe-critical COVID-19 as evaluated 14-28 days after 129 days post after administration (Sadoff et al., 2021b) . 131

The reactogenicity of the Ad26.COV2.S vaccine is short lived and acceptable and it was transient, 132 lower in those who were relatively old, and was of short duration (Sadoff et al., 2021a) . In the current 133 study, the first AstraZeneca-Oxford vaccine dose was associated with 34.7% of any type of 134 reactogenicity and the incidence of pain at the local site injection was 30.5%. In a phase 3 clinical trial, The study has a relatively small sample size and thus further studies with larger sample size is required 159 to ascertain the safety profile. In addition, a multi-center evaluation of the vaccine from KSA is needed 160 to examine the reactogenicity profile of the introduced SARS-CoV-2 vaccines. The study was also 161 predominated by male genders and a better proportion of male to female is needed to confirm the 162 gender predominance. 163

In conclusion, in this study, we observed no major side effects of the ChAdOx1-S and no reported 164 breakthrough infection during the observation period. There was a difference in the reported 165 symptoms between male and female and across the age group. personal relationships that could have appeared to influence the work 173

reported in this paper. 174 

Incidence of COVID-180 19 among returning travelers in quarantine facilities: A longitudinal study and lessons learned

Saudi Arabia: lessons learned, and the way forward

Estimated transmissibility 186 and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England

Sex and gender differences in the outcomes of vaccination 189 over the life course

Prime-boost interval matters: A 192 randomized phase 1 study to identify the minimum interval necessary to observe the h5 dna influenza 193 vaccine priming effect

Comparative systematic review and 195 meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj

BNT162b2 mRNA Covid-19 Vaccine

Safety and 203 immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old 204 adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Interim Results of a Phase 207 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Safety and Efficacy of Single-210

Dose Ad26.COV2.S Vaccine against Covid-19

Heterologous prime-boost COVID-19 213 vaccination: initial reactogenicity data

Analysis of thrombotic adverse reactions of covid-19 astrazeneca 216 vaccine reported to eudravigilance database

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the 221

ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 222 controlled trials in Brazil, South Africa, and the UK

CoV-2 by BNT162b2 vaccine-elicited sera